Pre-operative Stereotactic Radiosurgery Followed by Resection for Patients With Brain Metastases
Status: | Recruiting |
---|---|
Conditions: | Brain Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 6/22/2018 |
Start Date: | May 1, 2018 |
End Date: | February 28, 2021 |
Contact: | Amy Miller |
Email: | amym@iu.edu |
Phone: | 317-278-7614 |
A Phase II Study Analyzing Pre-operative Stereotactic Radiosurgery Followed by Resection for Patients With 1 - 4 Brain Metastases
This is a prospective, single arm, phase II trial to determine the local control at 6 months
utilizing pre-operative stereotactic radiosurgery followed by surgery within 1 - 3 days in
subjects with a diagnosis of 1-4 brain metastases and with an indication for surgical
resection of at least one brain metastasis at the discretion of a neurosurgeon.
utilizing pre-operative stereotactic radiosurgery followed by surgery within 1 - 3 days in
subjects with a diagnosis of 1-4 brain metastases and with an indication for surgical
resection of at least one brain metastasis at the discretion of a neurosurgeon.
Primary Objective To evaluate 6 month in-brain local control utilizing pre-operative
stereotactic radiosurgery followed by surgical resection for brain metastases.
Secondary Objectives
- Overall survival
- Distant in-brain progression
- Rate of leptomeningeal spread
- Rate of radiation necrosis
stereotactic radiosurgery followed by surgical resection for brain metastases.
Secondary Objectives
- Overall survival
- Distant in-brain progression
- Rate of leptomeningeal spread
- Rate of radiation necrosis
Inclusion Criteria
1. Radiographically confirmed solid tumor brain metastases
2. Criteria for surgical resection of at least one metastasis per neurosurgeon discretion
3. A diagnostic MRI Brain or CT Head demonstrating the presence of 1-4 solid tumor brain
metastases and lesion to be resected no more than 5 cm in any direction, performed
within 30 days prior to stereotactic radiosurgery. If multiple lesions are present,
then the total brain metastases volume can be no more than 30 cm3 excluding the lesion
to be resected.
4. For known primary, ds-GPA estimated median survival no less than 6 months
5. For unknown primary, GPA estimated median survival no less than 6 months
6. Surgical candidate per neurosurgeon discretion
7. Surgical resection able to be performed within 1 - 3 days after radiosurgery
8. Stereotactic radiosurgery candidate per radiation oncologist
9. ≥ 18 years old at the time of informed consent
10. Ability to provide written informed consent and HIPAA authorization
11. Platelet count > 100 k/cumm, Hgb > 7.5 gm/dL, INR < 1.3, ANC > 1.5 k/cumm
12. Patients currently on cytotoxic chemotherapy or immunotherapy are eligible, not
including anti-VEGF therapy
Exclusion Criteria
1. Patients who received anti-VEGF therapy within 6 weeks prior to enrollment, as there
is increased risk of fatal brain hemorrhage with surgical resection
2. Major medical illnesses or psychiatric impairments, which in the investigator's
opinion will prevent administration or completion of the protocol therapy and/or
interfere with follow-up
3. Patients with more than 4 brain metastases on MRI Brain or CT Head
4. Lesion to be resected is more than 5 cm
5. Total volume of metastatic disease more than 30 cm3 excluding lesion to be resected
6. Patients with leptomeningeal metastases documented by MRI or CSF evaluation
7. Previous whole brain radiation therapy
8. Previous radiation therapy to lesion to be resected
9. Planned adjuvant focal therapy including additional radiation therapy to the brain
10. Not a surgical candidate per neurosurgeon's discretion
11. Not a radiosurgical candidate per radiation oncologist's discretion
12. Surgery unable to be performed between 1 - 3 days after radiosurgery
13. Women who are pregnant or nursing are not eligible as treatment involves unforeseeable
risks to the fetus or child
14. Patients who have a known primary and have an estimated median survival less than 6
months per ds-GPA
15. Patients who have an unknown primary and have an estimated median survival less than 6
months per GPA
We found this trial at
3
sites
Indianapolis, Indiana 46202
Principal Investigator: Gordon A. Watson, MD, PhD
Phone: 317-278-7614
Click here to add this to my saved trials
Indianapolis, Indiana 46202
Principal Investigator: Gordon A. Watson, MD, PhD
Phone: 317-962-3172
Click here to add this to my saved trials
535 Barnhill Dr
Indianapolis, Indiana 46202
Indianapolis, Indiana 46202
(888) 600-4822
Principal Investigator: Gordon A. Watson, MD, PhD
Phone: 317-278-7614
Indiana University Melvin and Bren Simon Cancer Center At the IU Simon Cancer Center, more...
Click here to add this to my saved trials